Variant forms of cholestatic diseases involving small bile ducts in adults
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Cholestasis may result from diverse etiologies. We review chronic cholestatic disorders involving small intrahepatic bile ducts in the adult ambulatory care setting. Specifically, we discuss variant forms of primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) as well as other conditions that may present diagnostic and therapeutic difficulties. METHODS: We conducted a MEDLINE search of the literature (1981-1997) and reviewed the experiences at the Mayo Clinic. All articles were selected that discussed antimitochondrial antibody (AMA)-negative PBC, small-duct PSC (formerly pericholangitis), and idiopathic adulthood ductopenia. RESULTS: The most common chronic cholestatic liver diseases affecting adults are PBC and PSC. Patients without the hallmarks of either syndrome are diagnosed according to their clinical and histological characteristics. Autoimmune cholangitis is diagnosed if clinical and histological features are compatible with PBC but autoantibodies other than AMA are present. Isolated small duct PSC is diagnosed if patients have inflammatory bowel disease, biopsy features compatible with PSC, but a normal cholangiogram. If ductopenia (absence of interlobular bile ducts in small portal tracts) is found histologically in the absence of PSC, inflammatory bowel disease, and other specific cholestatic syndromes such as drug reaction or sarcoidosis, the most likely diagnosis is idiopathic adulthood ductopenia. CONCLUSIONS: Based on these definitions, an algorithm for diagnosis and therapy in patients with laboratory evidence of chronic cholestasis may be constructed, pending results of further investigations into the etiopathogenesis of these syndromes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lee, W. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021844 · Cited by 1,594
A Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Balkau, B., Eschwège, E., Poupon, R., & the UDCA–PBC Study Group* (1991) · New England Journal of Medicine · doi:10.1056/nejm199105303242204 · Cited by 755 · cited 1×
“Ursodeoxycholic acid (UDCA), a synthetic bile acid analog, improves hepatic biochemical abnormalities and increases survival in patients with AMA-positive PBC”
BackgroundUrsodiol for Primary Sclerosing Cholangitis
Lindor, K. D. (1997) · New England Journal of Medicine · doi:10.1056/nejm199703063361003 · Cited by 598
Self-citationUrsodiol for the Long-Term Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Poupon, R., & Balkau, B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405123301903 · Cited by 497 · cited 1×
“When the potential risks and benefits of treatment with prednisone v rsus UDCA are considered, it appears that UDCA should be used first for patients with autoimmune cholangitis, although it remains to be proven that the biochemical improvement seen in this group of patients translates into prolonged survival (32, 33).”
BackgroundUrsodeoxycholic acid in the treatment of primary biliary cirrhosis
Lindor, K. D., Dickson, E. R., Baldus, W. P., Jorgensen, R. A., Ludwig, J., Murtaugh, P. A., Harrison, J. M., Wiesner, R. H., Anderson, M. L., Lange, S. M., et al. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90021-3 · Cited by 487
Self-citationUrsodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial
Beuers, U., Spengler, U., Kruis, W., Aydemir, Ü., Wiebecke, B., Heldwein, W., Weinzierl, M., Pape, G. R., Sauerbruch, T., & Paumgartner, G. (1992) · Hepatology · doi:10.1002/hep.1840160315 · Cited by 448
Invernizzi, P., Crosignani, A., Battezzati, P. M., Covini, G., De Valle, G., Larghi, A., Zuin, M., & Podda, M. (1997) · Hepatology · doi:10.1002/hep.510250507 · Cited by 293
Michieletti, P., Wanless, I. R., Katz, A., Scheuer, P. J., Yeaman, S. J., Bassendine, M. F., Palmer, J. M., & Heathcote, E. J. (1994) · Gut · doi:10.1136/gut.35.2.260 · Cited by 236 · cited 3×
“PBC with positive ANA and/or ASMA (14).”
BackgroundEffects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis
Lindor, K., Therneau, T., Jorgensen, R., Malinchoc, M., & Dickson, E. (1996) · Gastroenterology · doi:10.1053/gast.1996.v110.pm8613058 · Cited by 228 · cited 1×
“When the potential risks and benefits of treatment with prednisone v rsus UDCA are considered, it appears that UDCA should be used first for patients with autoimmune cholangitis, although it remains to be proven that the biochemical improvement seen in this group of patients translates into prolonged survival (32, 33).”
BackgroundSelf-citationSmall-duct primary sclerosing cholangitis
Ludwig, J. (1991) · Seminars in Liver Disease · doi:10.1055/s-2008-1040417 · Cited by 166
Self-citation
Cited by
Extraintestinal manifestations and complications in IBD
Ott, C., & Schölmerich, J. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.117 · Cited by 351
Cholestatic phenotypes of autoimmune hepatitis
Czaja, A. J. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.08.039 · Cited by 63
“Abnormal serum AP or GGT level Serum AP level>2-fold ULN in 21% of classical AIH and never >4-fold ULN (14) Serum GGT level never >5-fold ULN (38, 39) PBC, PSC, small duct PSC, AMA-negative PBC (4, 14, 16, 45)”
BackgroundSakauchi, F., Mori, M., Zeniya, M., & Toda, G. (2006) · Journal of Epidemiology · doi:10.2188/jea.16.30 · Cited by 43
Farias, A. Q., Gonçalves, L. L., Bittencourt, P. L., De Melo, E. S., Abrantes‐Lemos, C. P., Porta, G., Nakhle, M. C., Carrilho, F. J., & Cancado, E. L. R. (2006) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2006.04130.x · Cited by 43
Metadata
- Authors
- Kim, W.
- Venue
- The American Journal of Gastroenterology
- Published
- 2000-05
- Volume
- 95
- Issue
- 5
- Pages
- 1130-1138
- ISSN
- 0002-9270 (ISSN-L)
- OpenAlex
- W2111411334
- Cited by
- 119
- References
- 13
- FWCI
- 4.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Variant forms of cholestatic diseases involving small bile ducts in adults. https://app.cochat.ai/papers/10.1016/s0002-9270(00)00791-7
- The paper
- Kim, W. (2000). Variant forms of cholestatic diseases involving small bile ducts in adults. The American Journal of Gastroenterology. https://doi.org/10.1016/s0002-9270(00)00791-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.